XNAS
ABVC
Market cap26mUSD
Oct 22, Last price
1.05USD
1D
4.73%
1Q
-8.93%
Jan 2017
-94.76%
IPO
105.51%
Name
ABVC Biopharma Inc
Chart & performance
P/E
—
P/S
—
EPS
—
Vol. 1Y
87.16%
Shs. 5Y
63.81%
Rev. 5Y
-6.20%
Div Yld LY
—
Div Yld TTM
—
Revenues
0
-100.00%
Net income
-8m
L+61.30%
CFO
-3m
L+65.07%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on creating novel drugs and medical devices to address critical, underserved healthcare requirements across the United States. The company's pipeline includes several key candidates: ABV-1501, currently undergoing Phase I/II clinical trials, is being developed as a combination treatment for triple-negative breast cancer. ABV-1504 has successfully completed Phase II clinical trials for major depressive disorders. ABV-1505 is progressing through Phase II clinical studies for attention deficit hyperactivity disorder (ADHD). ABV-1703 has concluded its Phase I clinical trials for the treatment of pancreatic cancer. ABV-1702 has also finished Phase I clinical investigations for myelodysplastic syndromes. ABV-1601 is in Phase I/II clinical trials, aimed at alleviating depression in individuals with cancer. ABV-1701 Vitargus is in development to treat conditions such as retinal detachment or vitreous hemorrhage. ABVC BioPharma maintains strategic alliances, including a co-development arrangement with Rgene Corporation, alongside collaborative agreements with BioHopeKing Corporation and BioFirst Corporation. The company's headquarters are located in Fremont, California, and it operates as a subsidiary of YuanGene Corporation.
Key people
Eugene Jiang
Chairman of the Board, Chief Business Officer · since 2019
Uttam Patil
Chief Executive Officer, Interim Chief Financial Officer · since 2024
Tsung-Shann Jiang
Chief Scientific Officer, Chief Strategy Officer, Director · since 2023
Chang-Jen Jiang
Director · since 2018
Shuling Jiang
Director · since 2022
Tsang Ming Jiang
Director · since 2017
Yen-Hsin Chou
Independent Director · since 2018
Yu- Min Chung
Independent Director · since 2022
Che-Wei Hsu
Independent Director · since 2022
Hsin-Hui Miao
Independent Director · since 2022
Yoshinobu Odaira
Independent Director · since 2018
Norimi Sakamoto
Independent Director · since 2018
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||